Beta Bionics announced today that it launched the integration of the iLet bionic pancreas with the Abbott (NYSE:ABT) ...

The US Food and Drug Administration has okayed removal of the contraindication for use during CT and MRI under certain ...

Abbott today announced that its FreeStyle Libre 2 and 3 systems can now be worn during common imaging procedures, such as X-rays, CT scans and MRIs*. The U.S. Food and Drug Administration (FDA) ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

Beta Bionics has launched the integration of its flagship iLet Bionic Pancreas with Abbott’s FreeStyle Libre 3 Plus sensor.

Abbott (NYSE: ABT) today released new data highlighting the emotional challenges faced by people living with type 2 diabetes, ...

Abbott has a strong leading position in their continuous glucose monitoring system with their Freestyle Libre brand. GLP-1 drugs have been rapidly adopted among patients with type 2 diabetes ...

Abbott’s Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span ...

Life sciences encompass fields like biochemistry and neuroscience, studying living organisms. The life sciences market is diverse, including pharmaceuticals with a value nearing $1.5 trillion.

IRVINE, CA / ACCESSWIRE / October 30, 2024 / Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes ...

The iLet is the first insulin delivery system in the United States to connect to Abbott's FreeStyle Libre 3 Plus sensor, whose readings every minute will help the iLet calculate insulin doses. When ...

The iLet is the first insulin delivery system in the United States to connect to Abbott's FreeStyle Libre 3 Plus sensor, whose readings every minute will help the iLet calculate insulin doses.